Chen Xiaoyan, Zhu Fan, Wang Bin, Zhou Yu, Xiong Hao, Fan Tao, Ke Wenjie
Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Department of Hepatobiliary Surgery, Ezhou Central Hospital, Ezhou 436099, China.
J Oncol. 2021 Jul 29;2021:6199732. doi: 10.1155/2021/6199732. eCollection 2021.
To investigate the clinical effect of iodine-125 seed implantation combined with chemotherapy in patients with primary liver cancer and the effect on peripheral blood Th1/Th2 cells.
A total of 136 patients with primary liver cancer from April 2017 to June 2018 were selected as subjects and randomly divided into the control group and observation group with 68 cases in each group. The control group was treated with chemotherapy, and the observation group was treated with iodine-125 seed implantation on the basis of the control group. After 3 months of treatment, the curative effect was investigated. Serum tumor markers, peripheral blood Th1/Th2 cells, and side effects and recurrence rate were compared between the two groups.
The levels of serum tumor markers in both groups at 3 months after treatment were lower than before treatment ( < 0.05). Three months after treatment, the levels of tumor markers AFP, AFP-L3, and GP73 in the observation group were 14.61 ± 3.49 g/L, 3.29 ± 0.41 ng/mL, and 51.24 ± 4.51 g/L, respectively, which were lower than those in the control group, 32.53 ± 4.59 g/L, 5.63 ± 0.63 ng/mL, and 71.52 ± 6.05 g/L ( < 0.05). At 3 months after treatment, the level of including interleukin-2 (IL-2) and tumor necrosis factor- (TNF-) in Th1 cells of the observation group was higher than that of the control group ( < 0.05), whereas the levels of IL-4, IL-6, and IL-10 in Th2 cells were lower than those in the control group ( < 0.05). There was no statistical significance in the incidence of leukopenia, thrombocytopenia, and gastrointestinal reactions between the two groups ( > 0.05). The recurrence rate of the observation group at 12, 24, and 36 months after treatment was lower than that of the control group ( < 0.05).
Iodine-125 seed implantation combined with chemotherapy in patients with primary liver cancer can reduce the level of serum tumor markers, improve the level of peripheral blood Th1/Th2 cells, and reduce the recurrence rate of patients without increasing the incidence of side effects, which is worthy of promoting the application of iodine-125 seed implantation.
探讨碘 - 125粒子植入联合化疗对原发性肝癌患者的临床疗效及对外周血Th1/Th2细胞的影响。
选取2017年4月至2018年6月收治的136例原发性肝癌患者作为研究对象，随机分为对照组和观察组，每组68例。对照组采用化疗治疗，观察组在对照组基础上采用碘 - 125粒子植入治疗。治疗3个月后，观察疗效，比较两组血清肿瘤标志物、外周血Th1/Th2细胞水平、不良反应及复发率。
两组治疗3个月后血清肿瘤标志物水平均低于治疗前（P<0.05）。治疗3个月后，观察组甲胎蛋白（AFP）、甲胎蛋白异质体L3（AFP-L3）、高尔基体蛋白73（GP73）水平分别为14.61±3.49μg/L、3.29±0.41ng/mL、51.24±4.51μg/L，低于对照组的32.53±4.59μg/L、5.63±0.63ng/mL、71.52±6.05μg/L（P<0.05）。治疗3个月后，观察组Th1细胞中白细胞介素 - 2（IL - 2）、肿瘤坏死因子 -α（TNF -α）水平高于对照组（P<0.05），而Th2细胞中IL - 4、IL - 6、IL - 10水平低于对照组（P<0.05）。两组白细胞减少、血小板减少及胃肠道反应发生率比较，差异无统计学意义（P>0.05）。观察组治疗后12、24、36个月复发率低于对照组（P<0.05）。
碘 - 125粒子植入联合化疗治疗原发性肝癌患者，可降低血清肿瘤标志物水平，提高外周血Th1/Th2细胞水平，降低患者复发率，且不增加不良反应发生率，值得推广应用碘 - 125粒子植入。
